peginterferon beta-1a

Home
Ligands
peginterferon beta-1a

GtoPdb Ligand ID: 7637

Synonyms: interferon beta 1-alpha | PEG-INF-β-1a | Plegridy®

peginterferon beta-1a is an approved drug (EMA and FDA (2014))

Compound class: Peptide or derivative

Comment: This drug is a PEGylated version of recombinant human interferon beta-1a [1].

Summary
Biological activity
Clinical data
References
Structure
Similar ligands
Immunopharmacology

No information available.

No information available.

Summary of Clinical Use
Approved for the treatment of relapsing-remitting multiple sclerosis. See Calabresi et al (2014) [2] for the reults of the Phase 3 ADVANCE clinical trial. (NCT00906399).

Summary of Clinical Use

Approved for the treatment of relapsing-remitting multiple sclerosis. See Calabresi et al (2014) [2] for the reults of the Phase 3 ADVANCE clinical trial. (NCT00906399).

Mechanism Of Action and Pharmacodynamic Effects
Interferon-beta-1a reduces the auto-immune attack on the protective sheath around the nerves which causes MS flare-ups, and thus reduces relapses. PEGylation of the cytokine increases the circulating half-life of the cytokine and thereby extends the administration interval to bi-weekly.

Mechanism Of Action and Pharmacodynamic Effects

Interferon-beta-1a reduces the auto-immune attack on the protective sheath around the nerves which causes MS flare-ups, and thus reduces relapses. PEGylation of the cytokine increases the circulating half-life of the cytokine and thereby extends the administration interval to bi-weekly.